TNF and rheumatoid arthritis: Similarly, a study conducted in Spain [34] demonstrated that among patients with moderate-to-severe RA refractory to csDMARDs and those that had previously undergone MTX treatment with inadequate responses to second-line TNF inhibitors, the combination of TOF and MTX resulted in more significant QALY gains, with total cost savings ranging from €5,783 to €13,975.